Gastrectomy for Bleeding Gastric Cancer During Ramucirumab plus Paclitaxel Therapy-A Case Report

• Published in: Gan to kagaku ryoho Vol. 46; no. 3; p. 586
• Main Authors: Mori, Kaori, Aoyama, Toru, Morita, Junya, Maezawa, Yukio, Amano, Shinya, Sawazaki, Sho, Numata, Masakatsu, Tamagawa, Hiroshi, Sato, Tsutomu, Oshima, Takashi, Yoshikawa, Takaki, Yukawa, Norio, Masuda, Munetaka, Rino, Yasushi
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.03.2019
• Subjects: Aged; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Female; Gastrectomy; Humans; Paclitaxel - therapeutic use; Ramucirumab; Stomach Neoplasms - drug therapy
• ISSN: 0385-0684

A 66-year-old woman diagnosed with advanced Stage Ⅳ gastric cancer(T4aN3M1[LYM])received RAM plus wPTX as third-line chemotherapy(ramucirumab 8mg/kg on the 1st and 15th day, paclitaxel 80mg/m2 on the 1st, 8th, and 15th day).After receiving 3 courses of this treatment, para-aortic lymphadenopathy had diminished but anemia had progressed because of tumor hemorrhage.Six weeks after the last administration of RAM, an open distal gastrectomy with D1 plus lymph node dissection and Billroth Ⅰ reconstruction was performed.The patient was discharged on the 9th day after surgery without complications such as postoperative bleeding and delayed wound healing.RAM plus wPTX therapy was restarted 6 weeks after the operation.Postoperative late complication there is no adverse event including adenocarcinoma and continues the same therapy at present.The perioperative treatment under the use of angiogenesis inhibitor has risk of postoperative bleeding and wound healing delay and includes surgery timing of treatment may be difficult.In our case, surgery was performed 6 weeks after the final administration of RAM.